ResMed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

RMD: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$42.90JphqnNnrybjfgh

ResMed Faces Near-Term Headwinds, but Long-Run Strategy and Outlook Sound

Business Strategy and Outlook

ResMed is taking a “smart devices” and “big data” approach to further entrench itself as one of the two leading players in the global sleep apnea market. The strategy is two-fold – accelerating diagnosis of the underpenetrated market and monitoring patient compliance which keeps diagnosed patients in the treatment net and payers happier to reimburse the cost of respiratory devices.

Sponsor Center